Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 251, Issue 1-2, Pages 14-24Publisher
ELSEVIER
DOI: 10.1016/j.jneuroim.2012.06.005
Keywords
Multiple sclerosis; Experimental autoimmune encephalomyelitis (EAE); T-regulatory cells; Brain derived neurotrophic factor (BDNF); Neuroprotection; Laquinimod
Categories
Funding
- Teva Pharmaceutical Industries (Israel)
Ask authors/readers for more resources
Laquinimod is an orally active molecule that showed efficacy in clinical trials in multiple sclerosis. We studied its effects in the CNS, when administered by therapeutic regimen to mice inflicted with experimental autoimmune encephalomyelitis (EAE). Laquinimod reduced clinical and inflammatory manifestations and elevated the prevalence of T-regulatory cells in the brain. In untreated mice, in the chronic disease stage, brain derived neurotrophic factor (BDNF) expression was impaired. Laquinimod treatment restored BDNF expression to its level in healthy controls. Furthermore, CNS injury, manifested by astrogliosis, demyelination and axonal damages, was significantly reduced following laquinimod treatment, indicating its immunomodulatory and neuroprotective activity. (C) 2012 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available